Form 8-K - Current report:
SEC Accession No. 0001193125-24-211645
Filing Date
2024-09-03
Accepted
2024-09-03 09:02:52
Documents
13
Period of Report
2024-08-29
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d862679d8k.htm   iXBRL 8-K 26282
  Complete submission text file 0001193125-24-211645.txt   149156

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA aldx-20240829.xsd EX-101.SCH 2841
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE aldx-20240829_lab.xml EX-101.LAB 17994
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aldx-20240829_pre.xml EX-101.PRE 11255
15 EXTRACTED XBRL INSTANCE DOCUMENT d862679d8k_htm.xml XML 3642
Mailing Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421
Business Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421 781-761-4904
Aldeyra Therapeutics, Inc. (Filer) CIK: 0001341235 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36332 | Film No.: 241272303
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)